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A small molecule that safely mimics the ability of
dietary restriction (DR) to delay age-related diseases
in laboratory animals is greatly sought after. We
and others have shown that resveratrol mimics ef-
fects of DR in lower organisms. In mice, we find
that resveratrol induces gene expression patterns
in multiple tissues that parallel those induced by
DR and every-other-day feeding. Moreover, resvera-
trol-fed elderly mice show a marked reduction in
signs of aging, including reduced albuminuria, de-
creased inflammation, and apoptosis in the vascular
endothelium, increased aortic elasticity, greater mo-
tor coordination, reduced cataract formation, and
preserved bone mineral density. However, mice fed
a standard diet did not live longer when treated
with resveratrol beginning at 12 months of age. OurCfindings indicate that resveratrol treatment has a
range of beneficial effects in mice but does not in-
crease the longevity of ad libitum-fed animals when
started midlife.
INTRODUCTION
In developed countries, much of the population now survives
to the point where chronic age-associated diseases such as
cardiovascular disease, cancer, diabetes, sarcopenia, osteo-
porosis, stroke, and kidney disease are major determinants of
morbidity and mortality (Crews, 2005). Numerous studies have
shown that dietary restriction (DR) alleviates many of these con-
ditions in mammals. Reduction of caloric intake to 30%–50%
below ad libitum levels, or every-other-day feeding (EOD) of a
nutritious diet, can delay the onset of age-related diseases,
improve stress resistance, and decelerate functional decline
(Barger et al., 2003; Goodrick et al., 1982; McCay et al., 1935).
Although DR has beneficial effects in humans (Heilbronn et al.,ell Metabolism 8, 157–168, August 6, 2008 ª2008 Elsevier Inc. 157
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Resveratrol Mimics Aspects of Dietary Restriction2006), such a diet is unlikely to be widely adopted and would
pose a significant risk to the frail, critically ill, or the elderly. As
such, we have focused on the development of ‘‘DR mimetic’’
compounds that provide some of the benefits of DR without a
reduction in caloric intake (Ingram et al., 2004). Strategies that
have been proposed include inhibition of glycolysis (2-deoxyglu-
cose) (Lane et al., 1998), enhancing insulin action (glucophage/
metformin) (Dhahbi et al., 2005), and small molecule activators
of SIRT1 (e.g., 3,5,40-trihydroxystilbene/resveratrol) (Howitz
et al., 2003).
Sirtuins are a family of NAD+-dependent deacetylases and
ADP ribosyltransferases that are homologous to the Saccharo-
myces cerevisiae Sir2 protein. Extra copies of SIR2 or its homo-
logs extend life span in yeast (Kaeberlein et al., 1999), worms
(TissenbaumandGuarente, 2001), and flies (Rogina andHelfand,
2004), and are proposed to underlie some of the physiological
effects of DR in simple organisms (Anderson et al., 2003; Lin
et al., 2000) and in mammals (Boily et al., 2008; Bordone et al.,
2007; Chen et al., 2005). To study sirtuins in mammals, we
employed resveratrol, a small polyphenol identified in an in vitro
screen for SIRT1 activators that can extend the life span ofS. cer-
evisiae (Howitz et al., 2003; Jarolim et al., 2004), Caenorhabditis
elegans (Viswanathan et al., 2005; Wood et al., 2004),Drosophila
melanogaster (Bauer et al., 2004; Wood et al., 2004), and the
vertebrate fish Nothobranchius furzeri (Valenzano et al., 2006),
although one group has failed to detect a significant effect in
worms or flies (Bass et al., 2007). In the first three species, life-
span extension is dependent on SIR2, and this has not yet been
tested forN. furzeri. Inobesemice, resveratrol improvesanumber
of health parameters, including glucose homeostasis, endur-
ance, and survival (Baur et al., 2006; Lagouge et al., 2006; Sun
et al., 2007), at least partly due to the increased activity of
SIRT1 and AMPK (Baur et al., 2006; Lagouge et al., 2006).
Here, we test the hypothesis that resveratrol imparts health
benefits by inducing DR physiology. At 1 year of age, C57BL/
6NIA mice were placed on a standard control diet (SD) or DR
by every-other-day feeding (EOD) with or without resveratrol.
We present evidence that long-term resveratrol treatment slows
age-related degeneration and functional decline and mimics the
gene expression patterns induced by DR.We discuss the poten-
tial implications of these findings for human health.
RESULTS
We previously reported that resveratrol improves the health and
survival of obese mice fed a high-calorie diet (Baur et al., 2006).
This raised two key questions: (1) Can resveratrol improve the
health of nonobese mice, and (2) if so is this due to an ability to
mimic the effects of DR? To answer these questions, we exam-
ined the effects of resveratrol on mice fed SD ad libitum, sub-
jected to EOD feeding, or fed a high-calorie diet (HC) ad libitum.
Initially, each dietary group was divided into no resveratrol (neg-
ative control; SD, EOD, or HC), low resveratrol (100 mg/kg of
food, SDLR, EODLR, or HCLR), or resveratrol (400 mg/kg of
food, SDR, EODR, or HCR). Later, additional groups of mice
were given a higher dose of resveratrol along with the standard
or HC diets (2400 mg/kg of food, SDHR, or HCHR). The HC
plus resveratrol (HCR) group was the subject of a previous158 Cell Metabolism 8, 157–168, August 6, 2008 ª2008 Elsevier Increport, and that nomenclature is preserved herein (Baur et al.,
2006).
Resveratrol Mimics Transcriptional Effects of DR
One of the most comprehensive ways to assess global changes
in physiology is to compare transcriptional changes across ma-
jor organs and tissues (Spindler, 2006). To test the hypothesis
that resveratrol is a mimetic of DR, we compared the transcrip-
tional profiles of resveratrol and EOD feeding in liver, skeletal
muscle, adipose, and heart. Z ratios were calculated for each
gene as described previously (Cheadle et al., 2003), and false
discovery rates were estimated using Rankprod (Hong et al.,
2006). A subset of the expression changes was verified by
RT-PCR (Figure S1). Most transcriptional changes induced by
resveratrol were subtle (fold change < 1.5) and tissue specific.
The ten largest changes induced by resveratrol treatment in
each tissue are listed in Table S1. In liver Cyp7A1, a rate-limiting
enzyme in the conversion of cholesterol to bile acids (Russell and
Setchell, 1992) was upregulated, while glucose-6-phosphatase,
a rate-limiting enzyme in the production of glucose (Trinh et al.,
1998), was repressed. In skeletal muscle and heart, numerous
transcripts involved in contractility were altered, while in white
adipose tissue (WAT) the most prominently affected transcripts
were beta defensins, antimicrobial peptides involved in innate
and adaptive immunity (Bowdish et al., 2006). The two changes
that were consistent across all four tissues based on the Rank-
prod analysis were reductions in the expression of the anion ex-
changer Slc4a1, and the interferon-inducible transcript Ifi27/
Isg12, which could indicate suppression of inflammatory re-
sponses.Microarray data on the effects of SIRT1 overexpression
in these tissues are not available, making it currently difficult to
assess whether SIRT1 is a mediator of these effects. No global
correlation with previous studies of SIRT1 overexpression in cul-
tured NIH 3T3 or b cells (Moynihan et al., 2005; Revollo et al.,
2004) was observed (data not shown).
To test the hypothesis that resveratrol treatment induces
global transcriptional changes that resemble EOD feeding, we
performed principal component analysis (PCA) on themicroarray
data from each tissue. Each principal component (PC) can be
roughly considered to represent a set of correlated changes in
gene expression and to be independent of every other PC.
PCs are ranked based on the contribution each makes to the to-
tal variability between samples. When the entire data set is used
to generate principal components, the effects of age and diet
predominate (data not shown); however, an effect of resveratrol
treatment can also be observed that parallels the changes in-
duced by EOD feeding. If the SD, SDR, and EOD groups are
used for PCA (eliminating the influence of age and HC diet), the
effects of resveratrol and EOD feeding correlate in the first PC
(i.e., the set of correlated changes making the greatest contribu-
tion to variability between groups) in liver, muscle, and adipose.
Restricting the analysis to differentially expressed genes
strengthens the correlation considerably (see Figures 1A [liver
versus muscle] and 1B [adipose versus heart]).
To comprehensively measure the variability between groups,
we calculated pairwise distances in high-dimensional space.
The position of each data point (microarray) is specified by the
expression levels of many different genes, each represented
mathematically as a distance in an independent spatial.
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be drawn, and its length is a reflection of the similarity between
the two microarrays in question. Such calculations were per-
formed for each pair of microarrays in each tissue, and the re-
sults are presented in Figure 1C, with deep red representing
a high degree of similarity, and white representing divergent
samples. These calculations also allow a statistical evaluation
of the hypothesis that resveratrol treatment shifted the overall
pattern of gene expression toward that induced by EOD feeding.
This conclusion could be reached based on spatial distances for
liver, muscle, and heart. The statistical power in adipose tissue
was limited by the number of samples, although the same trend
was apparent. Thus, the transcriptional effects of resveratrol and
EOD feeding show significant overlap in multiple tissues.
Although EOD feeding and conventional caloric restriction
(reducingdaily energy intakeby40%, ‘‘CR’’) share key features,
including extending mean and maximum life span, preventing
age-related disease, and improving insulin sensitivity, they have
not been shown to work through a common mechanism. There-
fore, we were interested in comparing our transcriptional profiles
of EOD and resveratrol treatment to previously reported effects
of CR. Differences in age, strain, gender, duration of treatment,
array platform, and tissue compound this analysis. Nonetheless,
by testing the overlap based on differential expression signatures
(Swindell, 2008), we detected significant associations between
either EOD feeding or resveratrol treatment and previous studies
of caloric restriction (Figure 1D). In the case of liver, the effects of
EOD and resveratrol treatment overlapped significantly with
those of CR for 5 of 7 published studies.
We next used parametric analysis of gene-set enrichment
(PAGE) to highlight specific functional pathways within the mi-
croarray data. Gene sets were obtained from the Molecular
Signatures Database (MSigDB, C2 collection) and analyzed as
described previously (Subramanian et al., 2005). Pathways that
were significantly altered by EOD feeding or resveratrol treat-
ment are presented in Figure 2A. The effects of the two treat-
ments were correlated (by direction of change) in 82% (liver),
76% (muscle), 96% (adipose), and 64% (heart) of the affected
Figure 1. Resveratrol and Dietary Restric-
tion Have Overlapping Effects on Gene
Expression
(A and B) Principal component analysis (PCA)
was performed on differentially expressed genes
from SD, SDR, and EOD for liver, muscle, adipose,
and heart. First PCs (the sets of correlated
changes that capture the most variability between
samples) for liver, muscle, and adipose are pre-
sented in (A) and (B). Each shows a shift of the
gene-expression pattern in resveratrol-treated
animals (SDR) toward that induced by every-
other-day feeding (EOD). In heart, the first PC did
not show this effect; however, the second PC
(shown) was nearly equal and did reveal a similar
shift. Error bars are 95% confidence intervals.
(C) Distances were calculated in high-dimensional
space for each pair of samples. Each square
shows the distance between two individual sam-
ples, ranging from zero (deep red; see compari-
sons to self on the diagonal) to highly divergent
(white). In each tissue, distances between SDR
and EOD samples (lower-right portion) tend to be
smaller than those to SD samples. p values were
determined by Kruskal-Wallis (nonparametric)
one-way ANOVA and are similar but slightly more
conservative than those obtained by standard
ANOVA.
(D) To compare our transcriptional profiles of EOD
and resveratrol treatment to published data on
10%–44% caloric restriction (Corton et al., 2004;
Dhahbi et al., 2005, 2006; Edwards et al., 2007;
Fu et al., 2006; Higami et al., 2004; Lee et al.,
2002; Selman et al., 2006; Tsuchiya et al., 2004),
we generated differential expression signatures
(Swindell, 2008). For each pair of transcriptional
profiles, the significance of the overlap in expres-
sion changes was evaluated by permutation test-
ing and adjusted for multiple comparisons using
the Benjamini-Hochberg Method (Benjamini and
Hochberg, 1995). Publicly available data sets are
assigned a name based on the tissue examined
and described in detail in Table S2. Shaded boxes
indicate significant associations (p < 0.05).Cell Metabolism 8, 157–168, August 6, 2008 ª2008 Elsevier Inc. 159
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Resveratrol Mimics Aspects of Dietary RestrictionFigure 2. Resveratrol Shifts Expression Patterns in Mice on a Standard Diet toward Those of Mice on a Calorie-Restricted Diet
(A) Parametric analysis of gene-set enrichment (PAGE) was performed on microarray data from mice fed a standard diet plus resveratrol (SDR) or subjected to
EOD feeding. Columns show every pathway significantly upregulated (red) or downregulated (blue) by either treatment at 27 months of age. The directions of
changes induced by resveratrol and EOD feeding were highly correlated in liver (82% of 503 pathways), muscle (76% of 398 pathways), and adipose (96% of
524 pathways), and weakly correlated (64% of 375 pathways) in heart.
(B) The effect of resveratrol and EOD onmitochondria-related pathways from the PAGE analysis for liver, skeletal muscle, adipose, and heart at 27months of age.
(C) The effect of resveratrol and EOD feeding on apoptosis-related pathways from the PAGE analysis for liver, skeletal muscle, adipose, and heart at 27 months of
age. Full names and Z scores for each of the pathways represented in (B) and (C) are presented in the Supplemental Data.
(D) PAGE analysis was reexamined to identify changes in transcriptional patterns between control (SD) mice at 18 and 27months of age for liver, muscle, adipose,
and heart. For each of the pathways found to be significantly different in the 18-month-old (‘‘younger’’) mice compared to 27-month-old mice (359, 270, 365, and
256 pathways in liver, muscle, adipose, and heart, respectively), the corresponding Z scores are also presented for EOD, SDR, and EODR mice at 27 months of
age (compared to the same 27-month-old controls).160 Cell Metabolism 8, 157–168, August 6, 2008 ª2008 Elsevier Inc.
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effects of DR in vivo. Among the notable changes were an in-
crease in mitochondrial gene expression in liver and muscle
(Figure 2B) and a decrease in apoptosis across the four tissues
(Figure 2C). Full names and Z scores for the gene sets in Fig-
ures 2 and S2 are presented in Table S5.
We also sought to identify changes in gene-expression pat-
terns that occur during normal aging and to test whether resver-
atrol treatment or DR resulted in more youthful gene-expression
patterns in the elderly mice. Based on a comparison between SD
fed mice at 18 and 27 months of age, gene-expression patterns
induced by either resveratrol treatment or EOD feeding in liver re-
sembled patterns frommice 9months younger (Figure 2D), while
in muscle this was only true for resveratrol treatment. In adipose
both EOD feeding and resveratrol enhanced changes that oc-
curred with aging, while in heart, neither treatment had a signifi-
cant effect. These results indicate that both resveratrol and EOD
feeding can slow the transcriptional changes that occur with
aging in some but not all tissues.
We previously showed that resveratrol opposes themajority of
the transcriptional changes in liver induced by an HC diet. Using
newly isolated RNA, a different array platform, and the current
version of the MSigDB pathways (1687 pathways versus 522 an-
alyzed previously), we have confirmed this result and extended
our analysis to three additional tissues: skeletal muscle, adipose,
and heart (Figure S2). These results from additional tissues sup-
port the conclusion that resveratrol treatment induces gene-
expression profiles that resemble mice on a lower-calorie diet.
Resveratrol Delays Functional Decline
Osteoporosis is a major age-associated disease in humans
(Gass and Dawson-Hughes, 2006). Resveratrol increases the
osteogenic response of osteoblasts (Su et al., 2007) and bone
density in ovariectomized rats (Liu et al., 2005), but the effect of
resveratrol on age-induced bone loss in normal mice has not
previously been tested. Following their natural deaths, femurs
were removed from mice (ages 30–33 months) and analyzed
bymicrocomputed tomography (microCT) andmechanical mea-
surements. In the distal femur, resveratrol significantly improved
the tissue mineral density (TMD) in SDLR and SDR compared to
SD control bones (Figure 3A), and tended to increase trabecular
thickness (p = 0.13). Cortical TMD (Figure 3B) trended higher in
resveratrol-treated groups (p = 0.14), and the effect was statisti-
cally significant when the two doses were pooled. In addition, re-
sveratrol significantly increased the bone volume to total volume
ratio over the entire femur in the SD fed mice (Figure 3C). Bone
strength was determined as the load that is endured by a bone
prior to failing in the 3 point bend test. Resveratrol caused a trend
toward increased maximum load (p = 0.18, Figure 3D); that ap-
proached statistical significance when the two doses were
pooled (p = 0.058). Overall, resveratrol improved the structure
and strength of the femurs tested, suggesting that it may
improve bone health.
The development of age-related cataracts involves mismigra-
tion of lens epithelial cells and the accumulation of reactive oxy-
gen species (Wolf et al., 2005). A pathologist trained in cataract
assessment in aging mice, and blinded to the groups, rated lens
opacity in live mice from 0 to 4 by half steps of 0.5, with 4 repre-
senting the complete lens opacity of a mature cataract. Consis-Ctent with previous studies (Wolf et al., 2000), the extent of cata-
ract formation significantly increased with age in ad libitum-fed
mice (Figure 3E). Strikingly, this increase was attenuated by
resveratrol treatment, which was more effective than EOD at
30 months of age.
Decreased locomotor function, resulting in the loss of balance
and coordination occurs with increasing age in humans and
rodents. To test the effect of resveratrol on locomoter function,
we measured the time to fall from an accelerating rotarod every
3 months. Rotarod is a task that contains a learning component
(Welsh et al., 2005), so it is normal to observe improved perfor-
mance over time. The SDR group, however, showed a pro-
nounced and statistically significant improvement at 21 and
24 months (Figure 3F), indicating that resveratrol improves
balance and motor coordination in aged animals.
Improved Vascular Function
Increased albuminuria is a marker of vascular dysfunction in
mice and a clinical marker of overall increased cardiovascular
risk in humans (Guzik and Harrison, 2007; Scalia et al., 2007).
Urine albumin/creatinine ratios were assessed in the SD, HC,
HCLR, and HCR groups at 21 and 26 months of age. The HC
mice, but not the HCLR or HCRmice, had significantly increased
albumin/creatinine ratios compared to SD controls at both time
points (Figure S3A), indicating that resveratrol affords protection
against vascular or kidney dysfunction.
Because the original cohort had reached an advanced age
and had fewmembers remaining, we assessed vascular function
in an additional cohort of mice placed on a diet containing
2400 mg/kg resveratrol at 12 months of age. Total plasma cho-
lesterol was significantly reduced in 22-month-old nonobese
mice (SDHR) following 10 months of resveratrol treatment (Fig-
ure S3B), while plasma triglycerides showed a slight trend to-
ward a decrease (Figure S3C). Fractionating pooled plasma
samples revealed that resveratrol reduced the amount of choles-
terol carried in all lipoprotein fractions (Figure S3D). One poten-
tial explanation for the decrease in circulating cholesterol is
diversion to bile acid synthesis via Cyp7A1, which was highly up-
regulated in the livers of resveratrol-treated animals (Table S1).
However, changes in bile acid pool sizes were not detected
(data not shown).
Aortic dysfunction and stiffening occur with increased age in
humans (Lakatta and Levy, 2003; Vaitkevicius et al., 1993), and
it has been suggested that resveratrol might be protective
against these effects (Labinskyy et al., 2006). Therefore, we in-
vestigated the effects of resveratrol (2400mg/kg/food) on vascu-
lar function in mice fed a SD or HC diet. Aortas of 3- (SD only) or
18-month-old animals were dissected and tested for respon-
siveness to the endothelium-dependent vasodilator acetyl-
choline (ACh). Both age-related and obesity-related functional
decline were prevented by resveratrol treatment (Figure 3G).
The responsiveness of aortas from SDHR mice was significantly
better than that of age-matched controls and comparable to that
of younger (SD, 3-month-old) controls. The HC diet significantly
worsened responsiveness, and the HCHR mice were protected
such that there was no difference between HCHR and age-
matched SD controls. The loss of ACh-induced relaxation with
aging and obesity was most likely due to increased superoxideell Metabolism 8, 157–168, August 6, 2008 ª2008 Elsevier Inc. 161
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(A) Femurs were removed following natural deaths between the ages of 30–33 months and analyzed by microcomputed tomography (microCT). In (A), distal tra-
becular tissue mineral density (TMD) was improved in SDLR and SDR compared to SD control bones (p < 0.05 for SDLR and p < 0.01 SDR versus SD control, *).
Error bars indicate SEM.
(B) Cortical TMD tended to increase with resveratrol treatment (p = 0.14). Error bars indicate SEM.
(C) Resveratrol significantly increased bone volume to total volume ratio over the entire femur in SD-fed mice (p < 0.05 for SDLR and p < 0.01 SDR versus
SD control, *); n = 5 for all groups in (A), (B), and (C). Error bars indicate SEM.
(D) Bone strength was tested in the postmortem femurs. Resveratrol treatment caused a trend toward increased maximum load (the load that is endured by
a bone prior to it failing in the three-point bending to failure test) (p = 0.18), n = 5 for SD and SDLR, and n = 4 for SDR. Error bars indicate SEM.
(E) Resveratrol treatment delayed the onset of age-related cataracts. Lens opacity was scored in living mice on a scale from 0 to 4 by half steps of 0.5, with
4 representing the complete lens opacity of a mature cataract. Age-related cataract development was significantly decreased at 30 months of age in SDR
mice compared to the SD control, whereas EOD feeding caused an early protective effect that was lost (p < 0.05, *). Error bars indicate SEM.
(F) Time to fall from an accelerating rotarod wasmeasured every 3months for all survivors from a predesignated subset of each group; n = 15 (SD), 11 (SDLR), and
16 (SDR). The SDR group improved significantly at 21 and 24 months versus 15 months (p < 0.05, #), showing increased motor coordination over time. Error bars
indicate SEM.
(G) Acetylcholine-induced relaxation in aortic ring preparations. Both age-related (SD, 18 months versus SD, 3 months) and obesity-related (HC, 18 months,
versus SD, 18 months) declines in endothelial function were prevented by resveratrol treatment. Preincubation with SOD restored ACh-induced relaxation
in the HC 18 month rings to youthful levels; n = 6 for each group. (&p < 0.05 versus SD [3 months], *p < 0.05 versus SD [18 months], and #p < 0.05 versus
HC [18 months]). Error bars indicate SEM.162 Cell Metabolism 8, 157–168, August 6, 2008 ª2008 Elsevier Inc.
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superoxide dismutase restored function (Figure 3G).
To directly measure levels of oxidative stress aortic rings were
incubated with dihydroethidine, which reacts with superoxide
to generate the fluorescent molecule ethidium bromide (EB).
Oxidative stress, as measured by EB fluorescence, increased
with age and was attenuated by resveratrol-treatment in aortas
from SD-fed mice (Figure S6P). Separately, mean EB fluores-
cence intensities were quantified in cross-sections of aortas
from the SD 3-month-old, SD 18-month-old, HC, and HCHR
mice (Figure S6Q). HC diet increased, and resveratrol attenu-
ated, oxidative stress, to the point where HCHR aortas were
not different from those of age-matched SD controls. These ex-
periments are summarized in Figure 3H.
Since nitric oxide (NO) is a key mediator of ACh-induced
vasorelaxation that is sensitive to oxidative stress, we measured
endothelial nitric oxide synthase (eNOS) expression. The resver-
atrol-treated mice displayed increased levels of eNOS mRNA,
suggesting an enhanced capacity for NO production (Figures
S6C and S6D), which could potentially help offset inactivation
by superoxide. NADPH oxidase is the primary source of O2
. in
vascular tissue, and gp91phox, its catalytic subunit, is upregu-
lated during aging in endothelial cells (Csiszar et al., 2007b). Ex-
pression of gp91phox was upregulated in response to aging and
HC diet, and in both cases, the effects were reversed by resver-
atrol treatment (Figures S6A and S6B). Consistent with these
data, vascular NADPH oxidase activity was increased in mice
fed a HC diet, and this was prevented by resveratrol treatment
(Figure S6O). Thus, resveratrol may enhance vasorelaxation by
both increasing NO and decreasing O2
.  production.
Apoptotic death of endothelial cells is thought to contribute
to vascular pathophysiology in aging and is attenuated by DR
(Csiszar et al., 2004). Since our PAGE analysis suggested that
resveratrol can suppress apoptosis (Figure 2C), we performed
TUNEL staining of aortas from SD 3-month-old, SD 18-month-
old, SDHR 18-month-old, HC 18-month-old, and HCHR 18-
month-old mice (Figures 3I and 3J). Apoptotic index (TUNEL-
positive nuclei as a percentage of total propidium iodide stained
endothelial cell nuclei) was increased by aging and further
increased by the HC diet, but these increases did not occur in
the presence of resveratrol (Figure 3K).
Inflammatory processes contribute to endothelial dysfunction
in aging (Csiszar et al., 2007a) and obesity (Roberts et al., 2006)
and are suppressed by DR. In agreement with in vitro studies
suggesting that resveratrol can reduce the production of
inflammatory cytokines and chemokines through inhibition of
NF-kB (Mayo et al., 2003), we found that age- and diet-related
increases in the expression of the inflammatory markers TNFa,CIL-6, IL-1b, ICAM-1, and iNOS were attenuated by resveratrol
treatment (Figures S6E–S6N). Consistent with these obser-
vations, we found that a number of pathways containing
NF-kB-responsive genes were suppressed in multiple tissues
during the PAGE analysis (see Table S5).
Survival
We have reported that resveratrol treatment increased the sur-
vival of mice fed a HC diet to 114 weeks of age (Baur et al.,
2006). Here, we provide the complete Kaplan-Meier survival
analysis (Figures 4B–4D) and maximum life span (final 20% sur-
viving) for the HC groups, as well as mice fed a standard diet or
placed on an EOD feeding regimen (Figure 4E). In the context of
the HC diet, resveratrol increased remaining life span of 1-year-
old mice by an average of 26% for the HCLR group (p = 0.005)
and 25% for HCR (p = 0.001) to the point where survival was
not significantly different from that of nonobese SD controls. In
the lower-dose (HCLR) group, maximum life span was also in-
creased, while this effect did not reach significance for the higher
dose (HCR) (Figure 4E). The major factor contributing to life span
extension in the resveratrol-treated HC groups was a reduction
in the number of deaths attributed to cardiopulmonary distress
(specifically, fatty changes in the liver combined with severe
congestion and edema in the lungs; Table S3).
Interestingly, the increases in longevity could be completely
uncoupled from changes in body weight. While the HCR group
had a very slight decrease in body weight that was not statisti-
cally significant, the HCLR group displayed a significant increase
in body weight, despite consuming a similar amount of food (Fig-
ures 4A, S4, and S5). Thus, the beneficial effects of resveratrol on
health and life span are not dependent on weight loss.
In the context of the standard diet, resveratrol did not increase
overall survival or maximum life span (Figures 4B and 4E). Impor-
tantly, the SD control group had a life span similar to that of
a much larger cohort of C57BL/6NIA mice (Turturro et al.,
1999). EOD feeding produced a trend toward increased longev-
ity compared to the SD control group, but the effect did not
reach statistical significance. Our results are consistent with
the previous observation that the effect of EOD on longevity is di-
minished in older C57BL/6 mice (Goodrick et al., 1990), which is
also true of DR by 40% restriction (Weindruch and Walford,
1982). Notably, EOD feeding in combination with the lower
dose of resveratrol did extend both mean and maximal life
span by 15% compared to SD controls (Figures 4C and 4E).
We have also tested the effect of a higher dose of resveratrol be-
ginning at 12months of age (SDHR) on life span, and again found
that longevity was not significantly affected. (Figure 4F).(H) Quantification of total nuclear ethidium bromide fluorescence as amarker of increased oxidative stress; n = 6 aortas for each group. This panel combines data
from two experiments shown separately in Figures S6P and S6Q. Both age-related (SD [18 months] versus SD [3 months]) and obesity-related (HC [18 months]
versus SD [18 months]) increases in oxidative stress were prevented by resveratrol treatment. (&p < 0.05 versus SD [3 months], *p < 0.05 versus SD [18 months],
and #p < 0.05 versus HC [18 months]). Error bars indicate SEM.
(I and J) Representative TUNEL staining of aortas frommice of the indicated ages and diets. Nuclei from apoptotic endothelial cells (intense green) in aortas of SD
[18 months] and HC [18 months] mice are highlighted in insets. Autofluorescence of elastic laminae (faint green) and nuclear counterstaining (propidium iodide,
red) are shown for orientation purposes.
(K) Apoptotic index (percentage of TUNEL-positive endothelial cell nuclei) was increased in the aortas of obese mice, and this change was prevented by resver-
atrol treatment; n = 6 aortas for each group; 10–15 images per aorta were analyzed. (&p < 0.05 versus SD [3 months], *p < 0.05 versus SD [18 months], #p < 0.05
versus HC [18 months]). Error bars indicate SEM.ell Metabolism 8, 157–168, August 6, 2008 ª2008 Elsevier Inc. 163
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on Longevity
(A) Mean body weights over the entire life span.
EOD feeding lowered body weight, and HC diet
increased it (p < 0.001). Resveratrol did not affect
body weight in mice fed the SD or EOD diets. The
HCLR group was significantly heavier than the HC
control group (p < 0.01), while the HCR group
showed a slight trend toward decreased body
weight that did not reach statistical significance.
Error bars indicate SEM.
(B) Kaplan-Meier Survival Analyses were per-
formed on the SD, SDLR, and SDR groups, and
the curves were not significantly different by the
logrank or Wilcoxon tests; n = 60 (SD), 55 (SDLR),
and 54 (SDR) at the beginning of the experiment.
(C) Kaplan-Meier Survival Analyses were per-
formed on the SD, EOD, EODLR, and EODR
groups. There were no significant differences be-
tween the three EOD diet groups; however, the
EODLR had increased survival compared to the
SD control group as determined by both logrank
(c2 = 7.46, p = 0.006) and Wilcoxon (p = 0.0016)
tests; n = 60 (SD) and 55 (EOD, EODLR, and
EODR) at the beginning of the experiment.
(D) Kaplan-Meier survival analyses were per-
formed on the SD, HC, HCLR, and HCR groups.
TheHCcontrol grouphaddecreasedsurvival com-
pared to the SD control group (logrank: c2 = 11.65,
p = 0.0006, Wilcoxon: p = 0.0003), whereas, sur-
vival in the HCLR and HCR groups did not differ
significantly from that of SD controls. When com-
pared to HC controls, survival was significantly
increased in both the HCLR group (logrank: c2 =
8.31, p = 0.004, Wilcoxon: p = 0.005) and the
HCR group (logrank: c2 = 4.83, p = 0.03,Wilcoxon:
p=0.001); n =60 (SD) and55 (HC,HCLR, andHCR)
at the beginning of the experiment.
(E) Maximum life span was calculated as the mean
of the final 20% of mice in each group as deter-
mined by Kaplan-Meier Analysis. Compared to the SD control group, the maximum life span was significantly increased in the EODLR (p = 0.03) and significantly
decreased in the HC control (p = 0.003) groups. In addition, HCLR had significantly increasedmaximum life span compared to theHC control group (p = 0.04), and
therewas a trend toward increased life span in HCRmice compared toHC controls. *, p < 0.05 versus SD control; #, p < 0.05 versus HC control. Error bars indicate
SEM.
(F) Kaplan-Meier Survival Analyses were performed on the SD and SDHR groups, and the curves were not significantly different. The earlier SD survival curve
(broken line) is shown for reference; n = 48 (SD, SDHR), and 60 (previous SD control) at the beginning of the experiment.Histopathology
Blinded postmortem histopathology for disease or predisease
states was performed on visceral organs including the heart, kid-
neys, liver, spleen, lungs, and pancreas (Table S3). Resveratrol
treatment did not significantly alter the distribution of patholo-
gies in SD groups. This included neoplasias, despite the potency
of resveratrol against implanted or chemically induced tumors,
recently reviewed elsewhere (Baur and Sinclair, 2006). This
may be related to the fact that the vast majority of these cases
were lymphomas, a tumor type for which the efficacy of resver-
atrol has not been thoroughly assessed, and that is thought to be
triggered mainly by endogenous retroviruses in mice (Kaplan,
1967; Risser et al., 1983).
DISCUSSION
Here we present a long-term evaluation of resveratrol as a DR
mimetic in mice. In agreement with a concurrent study (Barger164 Cell Metabolism 8, 157–168, August 6, 2008 ª2008 Elsevier Incet al., 2008), we show that resveratrol induces changes in the
transcriptional profiles of key metabolic tissues that closely re-
semble those induced by DR. In liver andmuscle, these changes
can also be correlated to the gene-expression patterns in youn-
ger animals, while in adipose tissue, the trend is reversed. Over-
all, health was improved under all dietary conditions, as reflected
by the reduction of osteoporosis, cataracts, vascular dysfunc-
tion, and declines in motor coordination; however, longevity
was increased only in the context of a HC diet, as reported
previously (Baur et al., 2006).
The effects of DR on longevity are diminished when the regi-
men is initiated at increasing ages (Goodrick et al., 1990; Wein-
druch and Walford, 1982), although many of the characteristic
transcriptional changes can be induced rapidly regardless of
age (Cao et al., 2001). Indeed, our EOD feeding regimen was
initiated at 12 months of age, and while average life span was in-
creased, the effect did not reach statistical significance, except
in combination with resveratrol (EODLR versus SD). Thus, it is.
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might have diminished the potential effects of resveratrol on life-
span in nonobese mice. To address this question, we are follow-
ing up with life-span studies in which resveratrol treatment is
begun at weaning. It may also be that resveratrol slows the gen-
eral age-related decline but does not impact the specific causes
of death in these mice. Indeed, resveratrol did not suppress
lymphoma, a major cause of mortality in C57BL/6 mice.
There is increasing evidence that the antiaging action of DR, at
least in part, stems from the attenuation of the age-associated
increase in oxidative stress (Sohal and Weindruch, 1996). In
particular, DR attenuates oxidative stress in the aortas of aged
rodents, and this may contribute to its vasoprotective effects
(Guo et al., 2002). Many of the changes we observed in resvera-
trol-treated animals involved a generalized reduction in oxidative
stress and inflammation, consistent with known effects of DR.
This was particularly apparent in the aorta, where a decrease
in superoxide production was detected directly (Figure 3H),
and a variety of transcripts related to inflammatory processes
were repressed (Figures S6E–S6N). These changes likely had
direct functional consequences, since ACh-induced responsive-
ness was restored by resveratrol treatment (Figure 3G). In addi-
tion, the reduction in cataract formation in resveratrol-treated
animals suggests that oxidative stress was reduced in the eye
(Figure 3E). One clear difference between EOD and resveratrol
was that EOD strongly upregulated glutathione metabolism,
whereas resveratrol had no effect. Thus, there may be differ-
ences in mechanisms by which EOD and resveratrol reduce ox-
idative stress. Another difference was that while both increased
expression of ribosomal proteins in liver, heart, and adipose, only
EOD had this effect in skeletal muscle. Since increased protein
synthesis in skeletal muscle has previously been implicated as
a major effect of DR (Lee et al., 1999), this result highlights a po-
tentially important difference in the resveratrol-treated animals.
Whether it is possible to find a DR mimetic that is also safe for
long-term consumption is of considerable debate in the field.
Throughout the experiment, mice were subjected to behavioral
tests and examined for signs of distress or disease. Postmortem
histopathological assessments were performed on mice from
all three dietary regimens (SD, EOD, and HC), with or without
resveratrol, and no obvious detrimental change was seen. Al-
though we did not find evidence for detrimental effects of long-
term resveratrol treatment at modest doses, we cannot rule
out the possibility that resveratrol exerted harmful effects that
limited its ability to extend life span. In a small pilot study using
7.5 times our highest dose (18,000 mg/kg resveratrol in the
food), five out of six mice died within 3–4 months, consistent
with an earlier study of extremely high doses in rats (Crowell
et al., 2004).
In conclusion, long-term resveratrol treatment of mice can
mimic transcriptional changes induced by dietary restriction
and allow them to live healthier, more vigorous lives. In addition
to improving insulin sensitivity and increasing survival in HC
mice, we show that resveratrol improves cardiovascular func-
tion, bone density, and motor coordination, and delays cata-
racts, even in nonobese rodents. Together, these findings con-
firm the feasibility of finding an orally available DR mimetic.
Since cardiovascular disease is a major cause of age-related
morbidity and mortality in humans but not mice, it is possibleCthat DR mimetics such as resveratrol could have a greater im-
pact on humans. However, resveratrol does not seem to mimic
all of the salutary effects of DR in that its introduction into the
diet of normal 1-year-old mice did not increase longevity.
EXPERIMENTAL PROCEDURES
Animals and Diets
Male C57BL/6NIA were purchased from the National Institute on Aging Aged
Rodent Colony (Harlan Sprague-Dawley, Indianapolis, IN). Beginning at
1 year of age, mice were fed a standard AIN-93G diet (SD and EOD) or
AIN-93G modified to provide 60% of calories from fat (HC) plus 0%, 0.01%,
or 0.04% resveratrol. Average daily doses over the course of the study
(mg/kg/day) were: 7.9 ± 0.2 (SDLR), 30.9 ± 0.6 (SDR), 7.6 ± 0.2 (EODLR),
30.4 ± 0.6 (EODR), 5.4 ± 0.2 (HCLR), 24.2 ± 0.8 (HCR), 204 ± 4 (SDHR), and
167 ± 16 (HCHR, ages 12–18 months). Additional details are provided in the
supplemental material.
MicroCT and Bone Strength
Femurs were removed following natural deaths between the ages of 30–33
months, and their architecture was analyzed on an EVS microCT MS-8
system (GE Healthcare, London, ON). Mechanical behavior of the femurs
was measured on an ELF 3200 test instrument (Bose Corp, Eden Prairie,
MN). Additional details are provided in the Supplemental Data.
Cataracts Assessment
Age-related lens opacity was scored in all living mice by an experienced
pathologist using a slit lamp, who was blinded as to the experimental groups.
Rotarod
Time to fall from an accelerating rotarod was measured for all survivors from a
predesignated subset of each group; n = 15 (SD), 11 (SDLR), and 16 (SDR). The
mice were tested at 15, 18, 21, and 24 months of age. At each time point the
mice were given a habituation trial at a constant speed of 4 rpm. The following
day, each mouse was given three trials, separated by 30 min rest periods,
during which the rotarod accelerated from 4 to 40 rpm over a period of 5 min.
Vessel Isolation and Functional Studies
Endothelial function was assessed as described previously (Csiszar et al.,
2007a, 2007b). In brief, aortas (n = 6 per group) were cut into ring segments
1.5 mm in length and mounted in myographs chambers (Danish Myo Technol-
ogy A/S, Inc., Denmark) for measurement of isometric tension. The vessels
were superfused with Krebs buffer solution (118 mM NaCl, 4.7 mM KCl,
1.5 mM CaCl2, 25 mM NaHCO3, 1.1 mM MgSO4, 1.2 mM KH2PO4, and
5.6 mM glucose at 37C and gassed with 95% air and 5%CO2). After an equil-
ibration period of 1 hr during which an optimal passive tension was applied to
the rings (as determined from the vascular length-tension relationship), they
were precontracted with 106 M phenylephrine and relaxation in response to
acetylcholine (ACh) over the range of 109 to 106 M was measured. In
some experiments rings were preincubated for 30minwith 200 U/mL superox-
ide dismutase to test the involvement of oxidative stress.
Apoptosis Assays
TUNEL assays were performed on aorta sections using the Apop Tag Fluores-
cein in Situ Apoptosis Detection Kit (Chemicon/Millipore, Billerica, MA),
according to manufacturer’s instructions, as previously described (Csiszar
et al., 2007b). Endothelial cells were identified by their anatomical location
(Ungvari et al., 2007).
Microarrays
RNA was extracted from liver, muscle, adipose, and heart at 18 or 27 months
of age and hybridized to Illumina Mouseref 8 whole genome microarrays (ver-
sion 1.1). Raw data were subjected to Z normalization as described previously
(Cheadle et al., 2003) and are available at http://www.ncbi.nlm.nih.gov/geo.
Gene set enrichment was tested using the PAGE method as previously
described (Kim and Volsky, 2005) and pathway definitions from MSigDB
(Subramanian et al., 2005). Pathways involving mitochondria and apoptosisell Metabolism 8, 157–168, August 6, 2008 ª2008 Elsevier Inc. 165
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provided by MSigDB while blinded to the data. Differentially expressed genes
were converted into differential expression signatures and used to evaluate
overlap with previously reported effects of 10%–44% CR as described previ-
ously (Swindell, 2008). Characteristics of the animals in 10%–44% restriction
studies are presented in Table S2. Additional details, including calculation of
principal components and pairwise distances, are provided in the Supplemen-
tal Data.
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Procedures, and Supplemental References and can be found with this article
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